Immuneering
IMRX
37 hedge funds and large institutions have $65.7M invested in Immuneering in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 21 reducing their positions, and 18 closing their positions.
5.56% less ownership
Funds ownership: 51.6% → 46.04% (-5.6%)
25% less capital invested
Capital invested by funds: $88.1M → $65.7M (-$22.4M)
26% less funds holding
Funds holding: 50 → 37 (-13)
67% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 18
67% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.08M |
| 2 |
BSW
Buckingham Strategic Wealth
Clayton,
Missouri
|
+$1.07M |
| 3 |
Millennium Management
New York
|
+$533K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$212K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$186K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$4.41M |
| 2 |
BlackRock
New York
|
-$4.09M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$874K |
| 4 |
State Street
Boston,
Massachusetts
|
-$808K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$682K |
IMRX Hedge Fund Activity: Q2 2022 in Review
37 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q2 2022, worth a combined $65.7M — down 25% from $88.1M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of IMRX and 6 opened new positions — a net loss of 12 holders — while 21 trimmed existing stakes and 7 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $3.08M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $4.41M sold.
- 37 institutional investors held Immuneering (IMRX) as of Q2 2022, down from 50 in Q1 2022.
- Funds reported $65.7M of Immuneering stock for Q2 2022, down 25% quarter-over-quarter.
- 6 funds opened new Immuneering positions in Q2 2022 and 18 closed out, a net change of -12 holders.
- The largest Immuneering buyer in Q2 2022 was T. Rowe Price Associates, an estimated $3.08M added.
- The largest Immuneering seller in Q2 2022 was Perceptive Advisors, an estimated $4.41M sold.
Based on aggregated 13F filings for Q2 2022.